Brief: Transgene: Positive Initial Data From A Phase 1 Trial With Oncolytic Virus TG6002

Transgene SA

08/09/2020 17:20

Sept 8 (Reuters) - TRANSGENE SA  TRNG.PA :
    * POSITIVE INITIAL DATA FROM A PHASE 1 TRIAL WITH
TRANSGENE’S
ONCOLYTIC VIRUS TG6002
    * INTRAVENOUS ADMINISTRATION OF TG6002 IS WELL TOLERATED AND
INDUCES THE PRODUCTION OF A CHEMOTHERAPY AGENT (5-FU) VIA ITS
REPLICATION IN TUMOR CELLS

Source text for Eikon:  ID:nBw2txrdDa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))